Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPECT-NP: Ceftolozane/tazobactam in Ventilated Nosocomial Pneumonia
NCT02070757Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ceftolozane + tazobactam in ventilator-associated pneumonia (VAP), sponsored by Merck & Co.. Started Sep 2014; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT02070757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070757.